Dear Sir, Please find the attached Disclosures under Regulation 30 and 37A as required by you.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Colinz Laboratories' Board, at its meeting on 14 October 2025, approved the sale of its factory at Sinnar, Nashik and its office premises at Bhandup West, Mumbai on a slump sale basis. The transactions are only enabling resolutions at this stage, with no buyer finalized and no deal price agreed. The buyer is described as an unrelated third party, with name withheld due to confidentiality. The transactions will require shareholder approval via a special resolution through postal ballot (15 October to 14 November 2025). The company says no material impact on financials is expected since consideration is expected to be roughly equal to the value of the assets being sold.
This is a preliminary step, not a confirmed sale, so no immediate change in operations or stock price is expected. If completed, the asset sale would free up capital but the company has indicated it is unlikely to materially affect earnings or business operations.